Tyra Biosciences, Inc.
Business
Tyra Biosciences is a clinical-stage biotechnology company developing precision small-molecule inhibitors targeting fibroblast growth factor receptor (FGFR) biology for oncology and genetically defined conditions. The company's lead program, oral dabogratinib, is in Phase 2 development for FGFR3-driven urothelial cancers and achondroplasia, with additional programs targeting FGFR4 in hepatocellular carcinoma and FGFR2 in intrahepatic cholangiocarcinoma. Tyra owns its proprietary SNÅP drug-design platform and retains full development and commercialization rights to its wholly-owned pipeline.
Summary from 10-K filed 2026-03-02
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 103 | 80 | 63 | 43 | 21 | |
| General and administrative | 30 | 24 | 17 | 16 | 6 | |
| Total operating expenses | 133 | 104 | 80 | 59 | 26 | |
| Loss from operations | −133 | −104 | −80 | −59 | −26 | |
| Interest and other income, net | 13 | 18 | 11 | — | — | |
| Total other income | 13 | 18 | 11 | 4 | −6,000 | |
| Net loss | −120 | −86 | −69 | −55 | −26 | |
| Unrealized gain (loss) on marketable securities available-for-sale, net | −377,000 | 389,000 | 381,000 | 0 | — | |
| Comprehensive loss | −120 | −86 | −69 | −55 | — | |
| Net loss per share, basic | −2.01 | −1.51 | −1.62 | −1.32 | −1.91 | |
| Net loss per share, diluted | −2.01 | −1.51 | −1.62 | −1.32 | −1.91 | |
| Weighted-average shares used to compute net loss per share - basic | 60 | 57 | 43 | 42 | 14 | |
| Weighted-average shares used to compute net loss per share - diluted | 60 | 57 | 43 | 42 | 14 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 77 | 92 | 58 | 251 | 302 | |
| Marketable securities | 179 | 249 | 145 | 0 | — | |
| Prepaid expenses and other current assets | 9 | 6 | 8 | 6 | 2 | |
| Total current assets | 265 | 347 | 212 | 257 | 304 | |
| Restricted cash | 1 | 1 | 1 | 1 | 243,000 | |
| Property and equipment, net | 1 | 2 | 2 | 1 | 1 | |
| Right-of-use asset | 6 | 6 | 7 | 2 | 1 | |
| Other long-term assets | 9 | 7 | 5 | 4 | 312,000 | |
| Total assets | 283 | 364 | 226 | 266 | 307 | |
| Accounts payable | 1 | 590,000 | 5 | 1 | 599,000 | |
| Lease liabilities, current | 472,000 | 412,000 | 280,000 | 140,000 | 202,000 | |
| Accrued expenses and other current liabilities | 16 | 14 | 10 | 4 | 3 | |
| Total current liabilities | 18 | 15 | 15 | 6 | 4 | |
| Lease liabilities, noncurrent | 5 | 6 | 6 | 2 | 981,000 | |
| Other long-term liabilities | 0 | 3,000 | 46,000 | 169,000 | 367,000 | |
| Total liabilities | 23 | 20 | 22 | 8 | 5 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 50,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024. | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 53,706,357 and 50,754,262 shares issued at December 31, 2025 and December 31, 2024, respectively, and 53,706,357 and 50,749,945 shares outstanding at December 31, 2025 and December 31, 2024, respectively. | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | |
| Additional paid-in capital | 630 | 594 | 369 | 354 | 342 | |
| Accumulated other comprehensive income | 393,000 | 770,000 | 381,000 | 0 | — | |
| Accumulated deficit | −371 | −251 | −165 | −96 | −40 | |
| Total stockholders' equity | 259 | 343 | 204 | 258 | 302 | |
| Total liabilities and stockholders' equity | 283 | 364 | 226 | 266 | 307 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 546,000 | 519,000 | 357,000 | 296,000 | 140,000 | |
| Stock-based compensation | 28 | 23 | 14 | 11 | 3 | |
| Accretion on marketable securities, net | −2 | −6 | −1 | 0 | — | |
| Prepaid expenses and other assets | −5 | −169,000 | −3 | −8 | −2 | |
| Accounts payable, accrued expenses and other liabilities | 3 | −744,000 | 9 | 2 | 1 | |
| Right-of-use assets and lease liabilities, net | 83,000 | 184,000 | −186,000 | 34,000 | 135,000 | |
| Net cash used in operating activities | −95 | −70 | −50 | −50 | −24 | |
| Purchases of marketable securities | −101 | −264 | −144 | 0 | — | |
| Maturities of marketable securities | 174 | 166 | 0 | — | — | |
| Purchases of property and equipment | −141,000 | −664,000 | −770,000 | −559,000 | −661,000 | |
| Net cash provided by (used in) investing activities | 72 | −98 | −145 | −559,000 | −645,000 | |
| Proceeds from issuances of common stock under benefit plans | 8 | 3 | 2 | 632,000 | 514,000 | |
| Proceeds from issuance of common stock and pre-funded warrants from Private Placement | 0 | 200 | 0 | — | — | |
| Payments of issuance costs for common stock and pre-funded warrants from Private Placement | 0 | −420,000 | 0 | — | — | |
| Net cash provided by financing activities | 8 | 202 | 2 | 632,000 | 311 | |
| Net cash increase (decrease) for the period | −15 | 34 | −193 | −50 | 287 | |
| Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | 68,000 | 0 | 125,000 | 0 | 209,000 | |
| Vesting of options early exercised subject to repurchase | 3,000 | 43,000 | 124,000 | 197,000 | — | |
| Receivable from exercise of stock options included in prepaid expenses and other current assets | 241,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Tyra Biosciences, Inc.'s CIK number?
Tyra Biosciences, Inc.'s SEC CIK number is 0001863127 (1863127). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Tyra Biosciences, Inc.'s SEC filings?
All of Tyra Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Tyra Biosciences, Inc. last report earnings?
Tyra Biosciences, Inc. (TYRA) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-220638). This is Tyra Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Tyra Biosciences, Inc.'s most recent earnings 8-K?
Tyra Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001193125-26-220638. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Tyra Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →